Corvus Pharmaceuticals, Inc. announced its financial results for Q4 and full year 2025, highlighting a successful public offering raising $189 million. The company reported positive data from its Phase 1 trial of soquelitinib for atopic dermatitis, indicating strong efficacy and safety.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.